Hypocretin pathology in human narcolepsy

Narcolepsy and Hypersomnia

Volumn , Issue , 2006, Pages 301-306

  Thannickal, Thomas C ^a   Siegel, Jerome M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875901266     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (19)

1. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6:991-997.
2. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27:469-474.
3. Honda Y, Doi Y, Juji T, Satake M. Narcolepsy and HLA: Positive DR2 as a prerequisite for the development of narcolepsy. Folia Psychiatr Neurol Jpn 1984; 38:360.
4. Thannickal TC, Siegel JM, Nienhuis R, Moore RY. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003; 13:340-351.
5. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001; 57:2253-2258.
6. John J, Wu MF, Siegel JM. Hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep 2000; 23:A12.
7. Siegel JM. Hypocretin administration as a treatment for human narcolepsy (Editorial). Sleep 2003; 26:932-933.
8. Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003; 26:953-959.
9. Wu MF, John J, Maidment N, Lam HA, Siegel JM. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol Regul Integr Comp Physiol 2002; 283:R1079-R1086.
10. John J, Wu MF, Maidment N, Lam HA, Boehmer LN, Patton M, et al. Increased activity reduces cataplexy in canine narcolepsy: Possible role of elevated hypocretin level. Sleep 2004; 27:049.
11. Wu MF, Nienhuis R, John J, Maidment N, Lam HA, Boehmer LN, et al. Effects of drugs affecting blood pressure and heart rate on the release of hypocretin in normal dogs. Sleep 2004; 27:077.
12. John J, Wu MF, Maidment NT, Lam HA, Boehmer LN, Patton M, et al. Developmental changes in CSF hypocretin-1 (orexin-A) level in normal and genetically narcoleptic Doberman pinschers. J Physiol 2004; 560:587-592.
13. Boehmer LN, Wu MF, John J, Siegel JM. Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 2004; 188:292-299.
14. Siegel JM, Nienhuis R, Gulyani S, Ouyang S, Wu MF, Mignot E, et al. Neuronal degeneration in canine narcolepsy. J Neurosci 1999; 19:248-257.
15. Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS, et al. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol 1999; 415:145-159.
16. Kiyashchenko LI, Mileykovskiy BY, Lai YY, Siegel JM. Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J Neurophysiol 2001; 85:2008-2016.
17. Siegel JM. Hypocretin (orexin): role in normal behavior and neuropathology. Annual Rev of Psychol 2004; 55:125-148.
18. Peever JH, Lai YY, Siegel JM. Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism. J Neurophysiol 2003; 89:2591-2600.
19. van den Pol AN, Gao XB, Obrietan K, Kilduff TS, Belousov AB. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci 1998; 18:7962-7971.